{"title":"奥达环素是治疗中重度社区获得性肺炎的潜在新药","authors":"D. Zappetti","doi":"10.1097/CPM.0000000000000316","DOIUrl":null,"url":null,"abstract":"Synopsis: Omadacycline is a new antibiotic, derived from the tetracycline class, which might fill the need for a novel antibiotic that is effective against the common bacterial organisms causing community-acquired pneumonia. This trial showed it to be noninferior to moxifloxacin. Source: Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517–527.","PeriodicalId":10393,"journal":{"name":"Clinical Pulmonary Medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/CPM.0000000000000316","citationCount":"0","resultStr":"{\"title\":\"Omadacycline is a Potential New Drug For Treatment in Moderate to Severe Community-acquired Pneumonia\",\"authors\":\"D. Zappetti\",\"doi\":\"10.1097/CPM.0000000000000316\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Synopsis: Omadacycline is a new antibiotic, derived from the tetracycline class, which might fill the need for a novel antibiotic that is effective against the common bacterial organisms causing community-acquired pneumonia. This trial showed it to be noninferior to moxifloxacin. Source: Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517–527.\",\"PeriodicalId\":10393,\"journal\":{\"name\":\"Clinical Pulmonary Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/CPM.0000000000000316\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pulmonary Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/CPM.0000000000000316\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CPM.0000000000000316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
摘要:奥马达环素是一种新的抗生素,衍生自四环素类,可能填补了对一种新型抗生素的需求,这种抗生素对引起社区获得性肺炎的常见细菌有机体有效。该试验表明其疗效不逊于莫西沙星。资料来源:Stets R, Popescu M, Gonong JR等。奥马达环素治疗社区获得性细菌性肺炎。中华医学杂志,2019;38(5):517 - 527。
Omadacycline is a Potential New Drug For Treatment in Moderate to Severe Community-acquired Pneumonia
Synopsis: Omadacycline is a new antibiotic, derived from the tetracycline class, which might fill the need for a novel antibiotic that is effective against the common bacterial organisms causing community-acquired pneumonia. This trial showed it to be noninferior to moxifloxacin. Source: Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380:517–527.
期刊介绍:
Clinical Pulmonary Medicine provides a forum for the discussion of important new knowledge in the field of pulmonary medicine that is of interest and relevance to the practitioner. This goal is achieved through mini-reviews on focused sub-specialty topics in areas covered within the journal. These areas include: Obstructive Airways Disease; Respiratory Infections; Interstitial, Inflammatory, and Occupational Diseases; Clinical Practice Management; Critical Care/Respiratory Care; Colleagues in Respiratory Medicine; and Topics in Respiratory Medicine.